We present the protocol of the Desire3R trial. Methods and analysis This multicentre open-label randomised trial will recruit 480 treatment-na?ve adults with advanced pleural mesothelioma, randomised (2:1) to either 3-weekly durvalumab 1500?mg plus 3-weekly doublet chemotherapy (cisplatin 75?mg/m2 or carboplatin, Area Under the Curve, AUC 5 and pemetrexed 500?mg/m2) 4C6 cycles, followed by 4-weekly durvalumab … Continue reading We present the protocol of the Desire3R trial